Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop Article Swipe

PDF

Reid W. Merryman , Loretta J. Nastoupil , John M. Timmerman , Andrew D. Zelenetz , Robert Kridel , Matthew J. Maurer , Bertrand Nadel , Andrea J. Radtke , Ann S. LaCasce ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1182/bloodadvances.2025018079

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents are under investigation, and early clinical data are encouraging. Aligning treatment with the underlying tumor biology and sequencing of therapies remain key clinical challenges. At the Lymphoma Research Foundation's biannual 2024 Follicular Lymphoma Scientific Workshop, experts convened to discuss the role of chemotherapy in the context of new therapies, the impact of early progression on treatment sequencing, novel endpoints in clinical trials, disease biology and the tumor microenvironment, and new treatments on the horizon. This report focuses on updates in FL biology, first-line treatment, the role of progression of disease in 24 months (POD24), clinical trial design, and redefining cure in FL.

Related Topics

Truth And Reconciliation Commission Of Canada

2025 Nba Draft

Concepts

No concepts available.

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1182/bloodadvances.2025018079
PDF: https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025018079/2469693/bloodadvances.2025018079.pdf
OA Status: gold
OpenAlex ID: https://openalex.org/W4416968887

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4416968887

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1182/bloodadvances.2025018079

Digital Object Identifier
Title: Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2025

Year of publication
Publication date: 2025-12-03

Full publication date if available
Authors: Reid W. Merryman, Loretta J. Nastoupil, John M. Timmerman, Andrew D. Zelenetz, Robert Kridel, Matthew J. Maurer, Bertrand Nadel, Andrea J. Radtke, Ann S. LaCasce

List of authors in order
Landing page: https://doi.org/10.1182/bloodadvances.2025018079

Publisher landing page
PDF URL: https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025018079/2469693/bloodadvances.2025018079.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025018079/2469693/bloodadvances.2025018079.pdf

Direct OA link when available
Cited by: 0

Total citation count in OpenAlex

Full payload

id	https://openalex.org/W4416968887
doi	https://doi.org/10.1182/bloodadvances.2025018079
ids.doi	https://doi.org/10.1182/bloodadvances.2025018079
ids.openalex	https://openalex.org/W4416968887
fwci
type	article
title	Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
is_xpac	False
apc_list.value	3000
apc_list.currency	USD
apc_list.value_usd	3000
apc_paid.value	3000
apc_paid.currency	USD
apc_paid.value_usd	3000
language	en
locations[0].id	doi:10.1182/bloodadvances.2025018079
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S2764683450
locations[0].source.issn	2473-9529, 2473-9537
locations[0].source.type	journal
locations[0].source.is_oa	True
locations[0].source.issn_l	2473-9529
locations[0].source.is_core	True
locations[0].source.is_in_doaj	True
locations[0].source.display_name	Blood Advances
locations[0].source.host_organization	https://openalex.org/P4310320990
locations[0].source.host_organization_name	Elsevier BV
locations[0].source.host_organization_lineage	https://openalex.org/P4310320990
locations[0].source.host_organization_lineage_names	Elsevier BV
locations[0].license	cc-by-nc-nd
locations[0].pdf_url	https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025018079/2469693/bloodadvances.2025018079.pdf
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id	https://openalex.org/licenses/cc-by-nc-nd
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Blood Advances
locations[0].landing_page_url	https://doi.org/10.1182/bloodadvances.2025018079
indexed_in	crossref, doaj
authorships[0].author.id	https://openalex.org/A5065588144
authorships[0].author.orcid	https://orcid.org/0000-0002-6360-3234
authorships[0].author.display_name	Reid W. Merryman
authorships[0].countries	US
authorships[0].affiliations[0].institution_ids	https://openalex.org/I4210117453
authorships[0].affiliations[0].raw_affiliation_string	Dana Farber Cancer Institute, Boston, Massachusetts, United States
authorships[0].institutions[0].id	https://openalex.org/I4210117453
authorships[0].institutions[0].ror	https://ror.org/02jzgtq86
authorships[0].institutions[0].type	facility
authorships[0].institutions[0].lineage	https://openalex.org/I4210117453
authorships[0].institutions[0].country_code	US
authorships[0].institutions[0].display_name	Dana-Farber Cancer Institute
authorships[0].author_position	first
authorships[0].raw_author_name	Reid W Merryman
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	Dana Farber Cancer Institute, Boston, Massachusetts, United States
authorships[1].author.id	https://openalex.org/A5037878906
authorships[1].author.orcid	https://orcid.org/0000-0001-6071-8610
authorships[1].author.display_name	Loretta J. Nastoupil
authorships[1].countries	US
authorships[1].affiliations[0].institution_ids	https://openalex.org/I4210097685
authorships[1].affiliations[0].raw_affiliation_string	Southwest Oncology, Durango, Colorado, United States
authorships[1].institutions[0].id	https://openalex.org/I4210097685
authorships[1].institutions[0].ror	https://ror.org/00zbyy251
authorships[1].institutions[0].type	healthcare
authorships[1].institutions[0].lineage	https://openalex.org/I4210097685
authorships[1].institutions[0].country_code	US
authorships[1].institutions[0].display_name	Southwest Women's Oncology
authorships[1].author_position	middle
authorships[1].raw_author_name	Loretta Nastoupil
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Southwest Oncology, Durango, Colorado, United States
authorships[2].author.id	https://openalex.org/A5066129729
authorships[2].author.orcid	https://orcid.org/0000-0003-4104-8943
authorships[2].author.display_name	John M. Timmerman
authorships[2].countries	US
authorships[2].affiliations[0].institution_ids	https://openalex.org/I2801403999
authorships[2].affiliations[0].raw_affiliation_string	UCLA Medical Center, Los Angeles, California, United States
authorships[2].institutions[0].id	https://openalex.org/I2801403999
authorships[2].institutions[0].ror	https://ror.org/04vq5kb54
authorships[2].institutions[0].type	healthcare
authorships[2].institutions[0].lineage	https://openalex.org/I2799798094, https://openalex.org/I2801403999
authorships[2].institutions[0].country_code	US
authorships[2].institutions[0].display_name	UCLA Medical Center
authorships[2].author_position	middle
authorships[2].raw_author_name	John M. Timmerman
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	UCLA Medical Center, Los Angeles, California, United States
authorships[3].author.id	https://openalex.org/A5061964017
authorships[3].author.orcid	https://orcid.org/0000-0003-1403-6883
authorships[3].author.display_name	Andrew D. Zelenetz
authorships[3].countries	US
authorships[3].affiliations[0].institution_ids	https://openalex.org/I1334819555
authorships[3].affiliations[0].raw_affiliation_string	Memorial Sloan Kettering Cancer Center, New York, New York, United States
authorships[3].institutions[0].id	https://openalex.org/I1334819555
authorships[3].institutions[0].ror	https://ror.org/02yrq0923
authorships[3].institutions[0].type	healthcare
authorships[3].institutions[0].lineage	https://openalex.org/I1334819555
authorships[3].institutions[0].country_code	US
authorships[3].institutions[0].display_name	Memorial Sloan Kettering Cancer Center
authorships[3].author_position	last
authorships[3].raw_author_name	Andrew D. Zelenetz
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	Memorial Sloan Kettering Cancer Center, New York, New York, United States
authorships[4].author.id	https://openalex.org/A5043505357
authorships[4].author.orcid	https://orcid.org/0000-0003-0287-7124
authorships[4].author.display_name	Robert Kridel
authorships[4].countries	CA
authorships[4].affiliations[0].institution_ids	https://openalex.org/I2802654988
authorships[4].affiliations[0].raw_affiliation_string	Princess Margaret Cancer Centre - UHN, Toronto, Ontario, Canada
authorships[4].institutions[0].id	https://openalex.org/I2802654988
authorships[4].institutions[0].ror	https://ror.org/03zayce58
authorships[4].institutions[0].type	healthcare
authorships[4].institutions[0].lineage	https://openalex.org/I1325899441, https://openalex.org/I2802654988
authorships[4].institutions[0].country_code	CA
authorships[4].institutions[0].display_name	Princess Margaret Cancer Centre
authorships[4].author_position	middle
authorships[4].raw_author_name	Robert Kridel
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	Princess Margaret Cancer Centre - UHN, Toronto, Ontario, Canada
authorships[5].author.id	https://openalex.org/A5059417970
authorships[5].author.orcid	https://orcid.org/0000-0002-1867-0526
authorships[5].author.display_name	Matthew J. Maurer
authorships[5].countries	US
authorships[5].affiliations[0].institution_ids	https://openalex.org/I1330342723
authorships[5].affiliations[0].raw_affiliation_string	Mayo Clinic, Rochester, Minnesota, United States
authorships[5].institutions[0].id	https://openalex.org/I1330342723
authorships[5].institutions[0].ror	https://ror.org/02qp3tb03
authorships[5].institutions[0].type	healthcare
authorships[5].institutions[0].lineage	https://openalex.org/I1330342723
authorships[5].institutions[0].country_code	US
authorships[5].institutions[0].display_name	Mayo Clinic
authorships[5].author_position	middle
authorships[5].raw_author_name	Matthew J Maurer
authorships[5].is_corresponding	False
authorships[5].raw_affiliation_strings	Mayo Clinic, Rochester, Minnesota, United States
authorships[6].author.id	https://openalex.org/A5108593592
authorships[6].author.orcid
authorships[6].author.display_name	Bertrand Nadel
authorships[6].countries	FR
authorships[6].affiliations[0].institution_ids	https://openalex.org/I4210144005
authorships[6].affiliations[0].raw_affiliation_string	Centre d'immunologie de Marseille Luminy, 13288 MARSEILLE, France
authorships[6].institutions[0].id	https://openalex.org/I4210144005
authorships[6].institutions[0].ror	https://ror.org/03vyjkj45
authorships[6].institutions[0].type	facility
authorships[6].institutions[0].lineage	https://openalex.org/I1294671590, https://openalex.org/I1294671590, https://openalex.org/I154526488, https://openalex.org/I21491767, https://openalex.org/I4210096427, https://openalex.org/I4210144005
authorships[6].institutions[0].country_code	FR
authorships[6].institutions[0].display_name	Centre d’Immunologie de Marseille-Luminy
authorships[6].author_position	middle
authorships[6].raw_author_name	Bertrand Nadel
authorships[6].is_corresponding	False
authorships[6].raw_affiliation_strings	Centre d'immunologie de Marseille Luminy, 13288 MARSEILLE, France
authorships[7].author.id	https://openalex.org/A5040104934
authorships[7].author.orcid	https://orcid.org/0000-0003-4379-8967
authorships[7].author.display_name	Andrea J. Radtke
authorships[7].countries	US
authorships[7].affiliations[0].institution_ids	https://openalex.org/I114662689
authorships[7].affiliations[0].raw_affiliation_string	Leica Microsystems, Bethesda, Maryland, United States
authorships[7].institutions[0].id	https://openalex.org/I114662689
authorships[7].institutions[0].ror	https://ror.org/012cvds63
authorships[7].institutions[0].type	company
authorships[7].institutions[0].lineage	https://openalex.org/I114662689
authorships[7].institutions[0].country_code	US
authorships[7].institutions[0].display_name	Leidos (United States)
authorships[7].author_position	middle
authorships[7].raw_author_name	Andrea Radtke
authorships[7].is_corresponding	False
authorships[7].raw_affiliation_strings	Leica Microsystems, Bethesda, Maryland, United States
authorships[8].author.id	https://openalex.org/A5085801543
authorships[8].author.orcid	https://orcid.org/0000-0001-7349-0176
authorships[8].author.display_name	Ann S. LaCasce
authorships[8].countries	US
authorships[8].affiliations[0].institution_ids	https://openalex.org/I4210117453
authorships[8].affiliations[0].raw_affiliation_string	Dana-Farber Cancer Institute, Boston, Massachusetts, United States
authorships[8].institutions[0].id	https://openalex.org/I4210117453
authorships[8].institutions[0].ror	https://ror.org/02jzgtq86
authorships[8].institutions[0].type	facility
authorships[8].institutions[0].lineage	https://openalex.org/I4210117453
authorships[8].institutions[0].country_code	US
authorships[8].institutions[0].display_name	Dana-Farber Cancer Institute
authorships[8].author_position	middle
authorships[8].raw_author_name	Ann S. LaCasce
authorships[8].is_corresponding	False
authorships[8].raw_affiliation_strings	Dana-Farber Cancer Institute, Boston, Massachusetts, United States
has_content.pdf	True
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025018079/2469693/bloodadvances.2025018079.pdf
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-12-03T00:00:00
display_name	Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
has_fulltext	False
is_retracted	False
updated_date	2025-12-04T23:47:47.292601
primary_topic
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1182/bloodadvances.2025018079
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S2764683450
best_oa_location.source.issn	2473-9529, 2473-9537
best_oa_location.source.type	journal
best_oa_location.source.is_oa	True
best_oa_location.source.issn_l	2473-9529
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	True
best_oa_location.source.display_name	Blood Advances
best_oa_location.source.host_organization	https://openalex.org/P4310320990
best_oa_location.source.host_organization_name	Elsevier BV
best_oa_location.source.host_organization_lineage	https://openalex.org/P4310320990
best_oa_location.source.host_organization_lineage_names	Elsevier BV
best_oa_location.license	cc-by-nc-nd
best_oa_location.pdf_url	https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025018079/2469693/bloodadvances.2025018079.pdf
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id	https://openalex.org/licenses/cc-by-nc-nd
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Blood Advances
best_oa_location.landing_page_url	https://doi.org/10.1182/bloodadvances.2025018079
primary_location.id	doi:10.1182/bloodadvances.2025018079
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S2764683450
primary_location.source.issn	2473-9529, 2473-9537
primary_location.source.type	journal
primary_location.source.is_oa	True
primary_location.source.issn_l	2473-9529
primary_location.source.is_core	True
primary_location.source.is_in_doaj	True
primary_location.source.display_name	Blood Advances
primary_location.source.host_organization	https://openalex.org/P4310320990
primary_location.source.host_organization_name	Elsevier BV
primary_location.source.host_organization_lineage	https://openalex.org/P4310320990
primary_location.source.host_organization_lineage_names	Elsevier BV
primary_location.license	cc-by-nc-nd
primary_location.pdf_url	https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025018079/2469693/bloodadvances.2025018079.pdf
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id	https://openalex.org/licenses/cc-by-nc-nd
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Blood Advances
primary_location.landing_page_url	https://doi.org/10.1182/bloodadvances.2025018079
publication_date	2025-12-03
publication_year	2025
referenced_works_count	0
abstract_inverted_index.24	131
abstract_inverted_index.At	64
abstract_inverted_index.FL	13, 120
abstract_inverted_index.In	25
abstract_inverted_index.an	29
abstract_inverted_index.in	83, 99, 119, 130, 140
abstract_inverted_index.is	3, 32
abstract_inverted_index.of	58, 81, 86, 91, 126, 128
abstract_inverted_index.on	94, 111, 117
abstract_inverted_index.to	18, 77
abstract_inverted_index.FL.	141
abstract_inverted_index.and	43, 56, 104, 108, 137
abstract_inverted_index.are	40, 47
abstract_inverted_index.key	61
abstract_inverted_index.new	87, 109
abstract_inverted_index.the	4, 52, 65, 79, 84, 89, 105, 112, 124
abstract_inverted_index.(FL)	2
abstract_inverted_index.2024	70
abstract_inverted_index.Many	37
abstract_inverted_index.This	114
abstract_inverted_index.cure	139
abstract_inverted_index.data	46
abstract_inverted_index.have	14
abstract_inverted_index.high	15
abstract_inverted_index.into	28
abstract_inverted_index.most	5, 20
abstract_inverted_index.role	80, 125
abstract_inverted_index.with	12, 34, 51
abstract_inverted_index.early	44, 92
abstract_inverted_index.novel	38, 97
abstract_inverted_index.rates	17
abstract_inverted_index.trial	135
abstract_inverted_index.tumor	54, 106
abstract_inverted_index.under	41
abstract_inverted_index.agents	39
abstract_inverted_index.common	6
abstract_inverted_index.impact	90
abstract_inverted_index.months	132
abstract_inverted_index.remain	60
abstract_inverted_index.report	115
abstract_inverted_index.biology	55, 103
abstract_inverted_index.context	85
abstract_inverted_index.design,	136
abstract_inverted_index.develop	21
abstract_inverted_index.discuss	78
abstract_inverted_index.disease	102, 129
abstract_inverted_index.experts	75
abstract_inverted_index.focuses	116
abstract_inverted_index.trials,	101
abstract_inverted_index.updates	118
abstract_inverted_index.(POD24),	133
abstract_inverted_index.Aligning	49
abstract_inverted_index.Although	10
abstract_inverted_index.Lymphoma	66, 72
abstract_inverted_index.Research	67
abstract_inverted_index.biannual	69
abstract_inverted_index.biology,	121
abstract_inverted_index.clinical	45, 62, 100, 134
abstract_inverted_index.convened	76
abstract_inverted_index.disease.	24
abstract_inverted_index.horizon.	113
abstract_inverted_index.indolent	7
abstract_inverted_index.lymphoma	1, 31
abstract_inverted_index.patients	11
abstract_inverted_index.response	16
abstract_inverted_index.therapy,	19
abstract_inverted_index.Workshop,	74
abstract_inverted_index.addition,	26
abstract_inverted_index.endpoints	98
abstract_inverted_index.lymphoma.	9
abstract_inverted_index.outcomes.	36
abstract_inverted_index.resistant	23
abstract_inverted_index.therapies	59
abstract_inverted_index.treatment	50, 95
abstract_inverted_index.Follicular	0, 71
abstract_inverted_index.Scientific	73
abstract_inverted_index.aggressive	30
abstract_inverted_index.associated	33
abstract_inverted_index.first-line	122
abstract_inverted_index.redefining	138
abstract_inverted_index.sequencing	57
abstract_inverted_index.therapies,	88
abstract_inverted_index.treatment,	123
abstract_inverted_index.treatments	110
abstract_inverted_index.underlying	53
abstract_inverted_index.challenges.	63
abstract_inverted_index.non-Hodgkin	8
abstract_inverted_index.progression	93, 127
abstract_inverted_index.sequencing,	96
abstract_inverted_index.unfavorable	35
abstract_inverted_index.Foundation's	68
abstract_inverted_index.chemotherapy	82
abstract_inverted_index.encouraging.	48
abstract_inverted_index.increasingly	22
abstract_inverted_index.investigation,	42
abstract_inverted_index.transformation	27
abstract_inverted_index.microenvironment,	107
cited_by_percentile_year
countries_distinct_count	3
institutions_distinct_count	9
citation_normalized_percentile